Welcome to our dedicated page for MALLINCKRODT PB CO news (Ticker: mckpf), a resource for investors and traders seeking the latest updates and insights on MALLINCKRODT PB CO stock.
Mallinckrodt PB Ltd Co, also known as MCKPF, is a global specialty pharmaceutical company focused on developing, manufacturing, and distributing specialty pharmaceutical products and therapies. They operate in the areas of autoimmune and rare diseases, neurology, rheumatology, hepatology, and more. Mallinckrodt recently announced FDA approval for their Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector, a new delivery device designed to help patients with chronic and acute inflammatory and autoimmune conditions administer Acthar Gel subcutaneously. With a track record spanning over 70 years and a commitment to patients, Mallinckrodt continues to provide innovative therapies and support programs.